More on ROIV

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-111.8% Growth)
- Ratings (9.3 Score)

Upcoming Events

- Earnings (11/16/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Roivant Sciences (NQ:ROIV)
Delayed: 33.62 -0.9 (2.61%)
Prev. Close $34.52  
Open$34.64 
52 Wk High$ 
52 Wk Low$ 
Day High$35.04 
Day Low$33.43 
P/E N/A  
EPS$ 
Volume2,070,938 

Friends, Peers and Foes (?): IMVT, ABUS, ROIVW, ABBV, AMGN (more...)

Aug 28, 2026 04:33 PM Form 144 Roivant Sciences Ltd. Filed by: Venker Eric
Aug 28, 2026 04:32 PM Form 8-K Roivant Sciences Ltd. For: Aug 28
Aug 28, 2026 06:49 AM H.C. Wainwright Reiterates Buy Rating on Roivant Sciences (ROIV)
Aug 27, 2026 05:25 PM Form 8-K Roivant Sciences Ltd. For: Aug 27
Aug 27, 2026 03:29 PM FDA approves Roivant's brepocitinib pill for dermatomyositis
Aug 27, 2026 03:29 PM FDA approves Priovant's brepocitinib for dermatomyositis treatment
Aug 27, 2026 03:29 PM Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Aug 27, 2026 03:29 PM Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
Aug 27, 2026 03:28 PM FDA approves Priovant's brepocitinib for dermatomyositis
Aug 27, 2026 03:28 PM Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
View All Articles

Entities mentioned with ROIV

View All Entities